Navigation Links
Sangamo BioSciences Reports Third Quarter 2009 Financial Results
Date:11/4/2009

alue=0.02) increase in small unmyelinated nerve fibers in the skin, or intraepidermal nerve fiber density (IENFD), in subjects with DN. Data were also presented that provided additional evidence of the positive effect of SB-509 on large fiber sensory nerve health as measured by improvements in nerve conduction velocity (NCV), in subjects with elevated markers of vascular damage (ICAM-1), and improvements in the muscle components of the neurologic exam (NIS-LL) 30-days after each of the three administrations of SB-509. Together these data confirm the neuroregenerative activity of SB-509 in patients with DN and define a drug-responsive population for future trials.
  • Completion of an underwritten public offering. On October 13, 2009, Sangamo closed an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $7.20 per share resulting in net proceeds of approximately $20.9 million after deduction of underwriting discounts and commissions and other offering expenses.
  • Expansion of licensing agreement with Sigma-Aldrich. Sigma-Aldrich Corporation and Sangamo announced a major expansion of our existing license agreement to include the exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals. Under the expanded agreement, Sigma also obtained rights to certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made initial payments of $20.0 million to Sangamo, consisting of an upfront license fee of $15.0 million and $5.0 million through the purchase of Sangamo's common stock at $7.86 per share. Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 million based on certain conditions and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. Sangamo is also eligible to receive commercial milestone payments ranging from $2.0 mil
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine news :

    1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
    2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
    3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
    4. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
    5. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
    6. Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
    7. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
    8. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
    9. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
    10. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
    11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
    (Date:7/9/2014)... This news release is available in French . ... different factors in 14 year old teens, including brain structure ... with 70% accuracy who will go on to develop binge ... lack of conscientiousness, and other variables such as life events ... likelihood of binge drinking. Whether or not the child ...
    (Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
    (Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
    (Date:7/8/2014)... and cardiovascular health as other healthy mature individuals, according ... Journal of Transplantation . The findings may provide some ... professionals caring for them. , Over the past two ... and older has become more common. Given the links ... removal of a kidney could make older donors vulnerable ...
    Breaking Medicine News(10 mins):Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:Study finds kidney donation safe for healthy older adults 2
    ... In this season of giving and sharing, St.,David,s Community ... $5.15 million in grants to area nonprofit organizations that ... "Especially this year, we ... care for Central Texans," said Earl Maxwell, CEO of ...
    ... Dec. 16 Globus Medical, Inc., the largest privately ... the appointment of Wendy DiCicco, CPA, as Chief Financial ... of a publicly traded medical device manufacturer to the ... she was the CFO for Kensey Nash Corporation (Nasdaq: ...
    ... 16 SunTrust Banks, Inc.,(NYSE: STI ... for employers seeking to take control of their ... administrative and financial,components, including a healthcare payment card, ... options, offered,through a single trusted custodial partner. , ...
    ... January 2009 issue, The Journal of Nuclear Medicine ... , "This change to the publication allows the ... structure and organization of research reports," said Heinrich R. ... of Nuclear Medicine . "Most important and critical, it ...
    ... The Body By Milk campaign -- famous for,putting white ... up with the,five-time GRAMMY(R)-Award winning and multi-platinum selling artist, Usher, ... the Body By,Milk got noise? music video program. , ... give 20 lucky teens the chance to flex their,creative muscle ...
    ... 16 December 2008 - The effectiveness of voriconazole in ... study to be featured in the International Journal ... Elsevier. Fungal infections can kill people with weakened immune ... or organ replacement, and the research reinforces earlier findings ...
    Cached Medicine News:Health News:$5.15 Million Provided to Support Local Health Care Needs 2Health News:$5.15 Million Provided to Support Local Health Care Needs 3Health News:$5.15 Million Provided to Support Local Health Care Needs 4Health News:Globus Medical Strengthens Executive Team with Appointment of CFO 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 3Health News:Journal of Nuclear Medicine premiers new, full-color design 2Health News:Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity 2Health News:Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity 3Health News:Voriconazole: A highly potent treatment for fungal infections 2
    (Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
    (Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
    (Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
    Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
    ... BOSTON, Jan. 27, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) ... the three months ended December 31, 2010 in the amount ... a result of instrument sales to over fifty Hospitals, Clinics, ... States. Solos looks towards continued growth in 2011 ...
    ... /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. ... the "Company"), a leading developer, manufacturer and marketer of ... and other health and nutritional products in the People,s ... products, Ranitidine Hydrochloride Capsule, has been added to the ...
    Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 3
    ... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
    ... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
    ... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
    ... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
    Medicine Products: